Leone Andrew R, Diorio Gregory J, Spiess Philippe E, Gilbert Scott M
Oncology (Williston Park). 2016 Jun;30(6):507-14.
Incidental identification of small renal masses (SRMs) has become increasingly common with widespread adoption of cross-sectional imaging. To date, early detection of SRMs has not translated to a substantial improvement in cancer-specific survival. Guidelines on the management of SRMs are evolving to reflect recent developments in treatment. The major approaches to managing SRMs include active surveillance, partial/radical nephrectomy, and ablative therapies, such as radiofrequency ablation with cryoablation. The goal of treatment is to optimize oncologic and renal function outcomes while avoiding overtreatment and associated morbidity. In this review, we summarize the diagnosis of SRMs, the role of renal mass biopsy, different treatment strategies, and future directions, including emerging molecular biomarkers.
随着横断面成像技术的广泛应用,偶然发现的小肾肿块(SRMs)越来越常见。迄今为止,SRMs的早期检测尚未转化为癌症特异性生存率的显著提高。SRMs的管理指南正在不断发展,以反映治疗方面的最新进展。管理SRMs的主要方法包括主动监测、部分/根治性肾切除术以及消融治疗,如射频消融和冷冻消融。治疗的目标是优化肿瘤学和肾功能结果,同时避免过度治疗及相关并发症。在本综述中,我们总结了SRMs的诊断、肾肿块活检的作用、不同的治疗策略以及未来方向,包括新兴的分子生物标志物。